-transparent.png){kind=logo}
The relationship between duration of treatment and biochemical parameters reflecting antiosteoclastic activity was studied in 26 patients with Paget's disease of bone receiving Cl2MDP 1600 mg/day. Six months after initiation of therapy, the reduction in total urinary hydroxyproline was not different in patients treated for 1, 3, 5, or 6 months. This remission lasted 1 year for all groups. In contrast, the longest treatment induced the greatest reduction in serum alkaline phosphatase. One year after the initiation of therapy, this reduction was sustained, whereas a slight relapse was noted in other groups. From these findings, it appears that a rapid bone load with oral Cl2MDP can induce a long-lasting reduction in bone resorption excess.
M C Chapuy, and
S A Charhon, and
P J Meunier
September 1979,
Lancet (London, England),
M C Chapuy, and
S A Charhon, and
P J Meunier
January 1980,
Advances in experimental medicine and biology,
M C Chapuy, and
S A Charhon, and
P J Meunier
October 1980,
Arthritis and rheumatism,
M C Chapuy, and
S A Charhon, and
P J Meunier
January 1984,
Metabolic bone disease & related research,
M C Chapuy, and
S A Charhon, and
P J Meunier
May 1984,
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
M C Chapuy, and
S A Charhon, and
P J Meunier
June 1983,
The New England journal of medicine,
M C Chapuy, and
S A Charhon, and
P J Meunier
August 1981,
The New England journal of medicine,
M C Chapuy, and
S A Charhon, and
P J Meunier
February 1994,
Seminars in arthritis and rheumatism,
M C Chapuy, and
S A Charhon, and
P J Meunier
February 1979,
Australian and New Zealand journal of medicine,
M C Chapuy, and
S A Charhon, and
P J Meunier
February 1994,
Seminars in arthritis and rheumatism,
